ASTC

Astrotech Corp (ASTC) 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended December 31, 2025, for Astrotech Corporation (Nasdaq: ASTC). The company develops and commercializes mass spectrometry (MS) and gas chromatography (GC) technology through wholly-owned subsidiaries, including 1st Detect (security detection), AgLAB (agriculture/cannabis), BreathTech (breath analysis), Pro-Control (industrial process control), and EN-SCAN (environmental testing). The company is classified as a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: For the three months ended Dec 31, 2025, revenue decreased by $113,000 (43%) compared to the prior year quarter, driven by lower instrument and grant revenue. However, for the six-month period, revenue increased by $150,000 (51%) year-over-year, primarily due to a $220,000 increase in grant revenue and higher consumables sales.
• Gross Margin: Gross margin contracted significantly to 5% for the quarter (down from 59% in the prior year) due to higher warranty costs and service expenses. For the six-month period, margin was 44% (down from 56%).
• Operating Expenses: Total operating expenses decreased by $567,000 (12.7%) for the quarter and $480,000 (5.9%) for the six months. This reduction was driven primarily by a decrease in Research and Development (R&D) spending due to lower consulting and material costs, partially offset by increased SG&A expenses related to a facility move and legal fees.
• Liquidity: Cash and cash equivalents remained stable at approximately $3.1 million. Short-term investments decreased from $15.1 million to $7.0 million as the company liquidated $8.4 million in investments to fund operations.

Outlook, Risks, and Management Commentary

• Capital Resources: Management believes current resources (cash and short-term investments totaling ~$10.1 million) are sufficient to fund operations for the next 12 months. However, the company may need to raise additional capital to execute long-term business plans. A Form S-3 registration statement was declared effective in January 2026 to facilitate future securities sales.
• Operational Milestones:
  • 1st Detect: Secured a DHS R&D contract for the TRACER 1000. Achieved the first TSA-approved sale of the TRACER 1000 ETD and deployed the first Narcotic Trace Detector (NTD) in Vietnam.
  • AgLAB: Field trials of the AgLAB 1000-D2 demonstrated yield improvements of 15-30% in cannabis distillation.
  • EN-SCAN: Launched a new subsidiary for environmental testing instruments in February 2025.
• Risks: The company faces significant customer concentration risk, with three customers accounting for substantially all revenue in the current six-month period. Other risks include uncertainty in government funding, supply chain inflation, and the need for additional capital. The company maintains a full valuation allowance against its net deferred tax assets due to cumulative losses.

Investor Verification Checklist

• Customer Concentration: Verify the stability of the three major customers representing nearly 100% of recent revenue.
• Cash Burn Rate: Monitor the rate of cash consumption against the $10.1 million liquidity position to assess the runway before potential dilution.
• Grant Revenue Sustainability: Assess the likelihood of recurring grant revenue, which drove the six-month revenue increase.
• TSA Certification Progress: Track the status of the TRACER 1000 Stage II testing and potential addition to the TSA "qualified" list, which is critical for 1st Detect's growth.
• Facility Move Impact: Confirm that the new Austin facility (Metric Facility) is fully operational and that associated costs are stabilizing.